Stockwinners Market Radar for December 23, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:26 EST Wynn Resorts CEO sells $1.8M in common stock - In a regulatory filing, Wynn Resorts disclosed that its CEO Matt Maddox sold 20K shares of common stock on December 23rd in a total transaction size of $1.80M, reducing his stake by about 5%.

19:09 EST Toll Brothers CEO sells $1.75M in common stock - In a regulatory filing, Toll Brothers disclosed that its CEO Douglas Yearley sold 25K shares of common stock on December 23rd in a total transaction size of $1.75M, reducing his stake by about 9%.

18:33 EST GoodRx co-CEO sells $4.47M in common stock - In a regulatory filing, GoodRx disclosed that its co-CEO Trevo Bezdek sold 129.4K shares of common stock on December 22nd in a total transaction size of $4.47M, reducing his stake by about 50%.

17:40 EST GlobalFoundries announces extension of AMD Wafer Supply Agreement - GlobalFoundries (GFS) announced that it has agreed to amend its Wafer Supply Agreement with AMD (AMD) to increase the volume of chips GF will supply as well as extend the terms of the agreement to secure supply through 2025. The agreement also expands the breadth of the partnership, including supply assurance for AMD chips serving the datacenter, personal computing, embedded and other growth markets. GF has been manufacturing high-performance chips for AMD for more than 12 years, and this new agreement extends this long-standing partnership to ensure supply for AMD's growing business. With this agreement, AMD now expects to purchase approximately $2.1B of wafers from GF between 2022 and 2025.

17:17 EST Raytheon Technologies awarded $250M U.S. Air Force contract modification - Raytheon Missiles and Defense has been awarded a modification totaling a $250M ceiling increase to previously awarded contract FA8672-17-D-0004 for a StormBreaker Small Diameter Bomb II integrated engineering change proposal by U.S. Air Force. This contract provides for design, development, integration, test and production engineering for changes to the SDB II GBU-53/B technical and production baseline. Work will be performed in Tucson, Arizona, and is expected to be completed by Aug. 22, 2027.

17:14 EST Lockheed Martin awarded $324.1M U.S. Navy contract modification - Lockheed Martin is awarded a $324.1M modification to a cost-plus-fixed-fee, firm-fixed-price order against a previously issued basic ordering agreement by U.S. Navy. This modification exercises options to support calendar year 2022 modification and retrofit activities for the F-35 Joint Strike Fighter program to include the procurement of material modification kits as well as program management, non-recurring engineering, aircraft induction, contractor field, depot site and laser shock peening site support.

17:13 EST Boeing awarded $239.6M U.S. Army contract - The Boeing Co was awarded a $239,590,243 cost-plus-fixed-fee contract for the Apache Improved Turbine Engine Integration Phase II by U.S. Army.

17:06 EST Freshworks and Zoho settle litigation filed by Zoho in March 2020 - Freshworks announced that it has resolved the litigation filed by Zoho in March of 2020 in federal court in California for trade secret misappropriation against Freshworks. Following the filing of the lawsuit, Freshworks determined that a now-former Freshworks sales employee, using his spouse's computer without her knowledge, wrongfully accessed and used Zoho confidential information relating to sales leads. These actions were not taken at the direction of Freshworks, and are contrary to Freshworks' policies. Freshworks has taken steps to remediate any harm caused and agreed to take steps to make sure that nothing like this happens again. Freshworks and Zoho have settled the litigation, and Zoho has now dismissed the lawsuit, bringing it to an end.

17:03 EST Par Pacific sees FY22 CapEx, turnaround outlay $70M-$80M - Par Pacific announced its 2022 capital expenditure and turnaround outlay guidance with a range of $70M-$80M. Approximately $30M in Washington refinery turnaround outlays are expected during the first quarter of 2022. Remaining capital expenditures include approximately $35M of maintenance, regulatory, and IT spend and approximately $10M of growth capital.

17:01 EST Escalade names Walter Glazer, Jr. as CEO - The Board of Directors of Escalade is pleased to announce the appointment of Walter Glazer, Jr. as full-time CEO and President effective January 1, 2022. Glazer has been serving as interim CEO and President.

16:23 EST Holland America Line's Zuiderdam cruise ship returned to service - Carnival states that its "Holland America Line's Zuiderdam returned to service from Port of San Diego in California, the second Holland America ship to resume service in San Diego since the industrywide pause. Zuiderdam joins Koningsdam, which resumed service in San Diego Oct. 10. Holland America Line now has six ships cruising again in the Caribbean, Mexico and along the Pacific Coast of the United States."

16:18 EST Check-Cap receives Nasdaq minimum bid price notification - Check-Cap announced that the company received a letter from the Nasdaq Listing Qualifications indicating that the company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Further, the Rules also provide the company a compliance period of 180 calendar days to regain compliance. According to the Letter, the company has from December 23, 2021, or until June 21, 2022, to regain compliance with the minimum bid price requirement.

16:16 EST DBDR Tech Acquisition Corp. approves combination with CompoSecure - Roman DBDR Tech Acquisition Cor announced that its stockholders have approved all proposals related to the previously announced proposed business combination with CompoSecure Holdings, L.L.C., a "leading provider of premium financial payment cards and emergent provider of cryptocurrency storage and security solutions", at a special meeting of Roman DBDR stockholders held today. The closing of the Business Combination is anticipated to occur on or about December 27, 2021.

16:10 EST Four Corners Property Trust to acquire Circle K property for $3.2M - Four Corners Property Trust announces the acquisition of a Circle K property for $3.2M. The property is located in a dense corridor in Illinois and is corporate-operated with approximately three years of term remaining. The transaction was priced at a 7.2% capitalization rate on current rent and exclusive of transaction costs.

16:06 EST Guardion Health Sciences to wind down VectorVision business - Guardion Health "announced that, as part of its ongoing comprehensive evaluation of its business, it will wind down the business operations of its VectorVision business and, instead, focus on exploiting its valuable intellectual property and technology using a restructured and more cost-efficient approach. The company is exploring both domestic and international business opportunities, such as licensing and distribution arrangements, with qualified parties, to assist the company in the economic exploitation of these intellectual property rights, including the VectorVision patents. As a result of this change to the VectorVision business strategy, management believes that it will be able to better focus its efforts and deploy capital to more growth-oriented brands and product lines, such as Viactiv, and other products in development, that it hopes to expeditiously bring to market in 2022. The company expects the wind-down to be completed by approximately March 31, 2022."

14:25 EST Endo announces pact to settle Texas opioid cases and claims - Endo International plc announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc. have entered into a statewide settlement agreement intended to resolve all government-related opioid claims in Texas. Endo said: "The settlement, which is subject to certain conditions and contingencies, provides a framework through which Endo and its subsidiaries can fully and finally resolve the opioid-related claims of Texas and its subdivisions in exchange for a total payment of $63M. The settlement includes no admission of wrongdoing, fault or liability of any kind by Endo or its subsidiaries, and the settlement value should not be extrapolated to any other opioid-related cases or claims. The Texas settlement resolves, among other things, claims against Endo's subsidiaries in two cases set for trial in Texas state court in 2022: County of Dallas v. Purdue Pharma, L.P., et al., Texas MDL Pretrial Cause No. 2018-77098, and County of Bexar v. Purdue Pharma, L.P., et al., Texas MDL Pretrial Cause No. 2018-77066. The plaintiffs in those cases agreed to sever Endo's subsidiaries from these upcoming trials pending implementation of the settlement. The company is continuing to litigate opioid claims not covered by its settlements and to pursue settlements that it believes are in its best interests while remaining focused on its primary goal of achieving a global settlement. At the same time, Endo is exploring other strategic alternatives, and may seek to implement one or more of those alternatives in the event it is unable to achieve a global settlement. Endo cannot speculate on the likelihood, nature or timing of any outcome."

14:09 EST Marathon Digital says to purchase 'record number' of Antminer S19 XP miners - Marathon Digital announced that it has entered into a contract with BITMAIN to purchase "a record number" of ANTMINER S19 XP bitcoin miners. Based on current delivery schedules, Marathon anticipates all newly purchased miners to ship from BITMAIN between July 2022 and December 2022. "In conjunction with this purchase, Marathon will be upgrading a portion of its mining fleet with the latest mining hardware to increase the overall efficiency of the company's operations. As a result, the company's mining operations are now expected to consist of approximately 199,000 bitcoin miners producing approximately 23.3 EH/s, making Marathon one of the largest known publicly traded bitcoin miners in the world once all miners are fully deployed and operational," the company said. "Given the strength of our balance sheet and our asset-light model, which allows us to invest our capital into mining machines rather than infrastructure, we were uniquely positioned to place the largest single order of S19 XPs, in terms of total hash rate, BITMAIN has ever received. With this latest purchase of S19 XPs, we will be growing our Bitcoin mining operations to approximately 199,000 total miners and 23.3 EH/s by early 2023. This growth represents more than a 600% increase from our current hash rate and a 75% increase from our prior projection of 13.3 EH/s by the middle of 2022. With 23.3 EH/s of total capacity expected to be online in early 2023 and ample access to renewable power behind the meter with one of the largest renewable energy providers in North America, we believe we have established Marathon as one of the leading bitcoin miners in North America and potentially the largest known miner in the world," said Fred Thiel, Marathon's CEO.

13:39 EST Virgin Group reports intent to to purchase up to $100M of Virgin Orbit stock - Virgin Orbit, which has announced a planned business combination with NextGen Acquisition Corp. II, announced Virgin Group's intent to purchase up to $100M of Virgin Orbit common stock in an additional PIPE investment at a price per share of $10.00. NextGen Acquisition Corp. II's Sponsor will be supporting a portion of the Additional Equity Amount alongside the Virgin Group. The Additional Equity Amount will be determined by the amount of investment, if any, required to satisfy the minimum cash condition as defined in the merger agreement up to a maximum amount of $100M, the company said in a statement. "I am committed and confident in the future of Virgin Orbit and its life ahead as a public company," said Sir Richard Branson, Founder of Virgin Orbit. "This investment will ensure that Virgin Orbit has the capital required to go and build upon its incredible foundation and continue its rapid transition into a successful commercial space launch company. I couldn't be more thrilled to watch it continue its journey into the public markets."

13:05 EST Mercury Systems jumps 5% after Bloomberg says Jana to push for sale

13:02 EST Baker Hughes reports U.S. rig count up 7 to 586 rigs

12:20 EST Luminar boosts stock buyback plan to over $300M - Luminar Technologies announced the successful execution of its previously announced transaction, with the intent to purchase shares and accelerate growth. The deal was oversubscribed based on positive institutional investor support, and upsized to a total of $625M in gross proceeds. Luminar expects to use over $300M of the proceeds for LAZR share purchases, while the remaining capital will bolster Luminar's balance sheet. Luminar intends to use the net proceeds to accelerate business growth including: series production capacity expansion, new commercial wins, technology roadmap advancement, international expansion, and accelerating software development. Luminar remains on track to enter the series production phase by the end of 2022.

12:00 EST Altus Power falls -7.7% - Altus Power is down -7.7%, or -84c to $10.11.

12:00 EST Zhangmen Education falls -28.0% - Zhangmen Education is down -28.0%, or -$2.37 to $6.11.

12:00 EST Lightning eMotors rises 19.6% - Lightning eMotors is up 19.6%, or $1.15 to $6.97.

11:15 EST Merck expects to produce 10M courses of molnupiravir treatment by end 2021 - Merck said: Global access has been a priority for Merck and Ridgeback since the inception of their molnupiravir collaboration. The companies are committed to providing timely access to molnupiravir globally through our comprehensive supply and access approach, which includes investing at risk to produce millions of courses of therapy; tiered pricing based on the ability of governments to finance health care; entering into supply agreements with governments; and granting voluntary licenses to generic manufacturers and to the Medicines Patent Pool to make generic molnupiravir available in more than 100 low- and middle-income countries following local regulatory authorizations or approvals. In anticipation of the results from MOVe-OUT and the potential for regulatory authorization or approval, Merck has been producing molnupiravir at risk and expects to produce 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022. Merck entered into a procurement agreement with the U.S. Government under which the company will supply approximately 3.1 million courses of molnupiravir to the U.S. Government, upon Emergency Use Authorization or approval from the U.S. Food and Drug Administration. Merck has entered into advance purchase and supply agreements for molnupiravir with the governments of over 30 countries worldwide, including Australia, Canada, Korea, Japan, Thailand, United Kingdom and United States, pending regulatory authorizations, and is currently in discussions with additional governments. Merck plans to implement a tiered pricing approach based on World Bank country income criteria to reflect countries' relative ability to finance their health response to the pandemic. As part of its commitment to widespread global access, Merck previously announced that it has entered into a licensing agreement with the Medicines Patent Pool to increase broad access for molnupiravir in low- and middle-income countries. Additionally, Merck previously announced that the company has entered into non-exclusive voluntary licensing agreements for molnupiravir with established generic manufacturers to accelerate availability of molnupiravir in more than 100 low- and middle-income countries following approvals or emergency authorization by local regulatory agencies. Merck continues to discuss additional measures and collaborations to accelerate broad, global access to molnupiravir."

11:00 EST Hallmark decides to discontinue pursuit of IPO to separate Specialty Commerce - Hallmark Financial Services announced that it is no longer actively pursuing the previously announced separation of its Specialty Commercial business segment. As a result, the Company does not intend to proceed with the previously announced initial public offering of the specialty commercial business. Current evaluations by Hallmark's board of directors note the significant progress achieved over the past 18 months, including the successful completion of a loss portfolio transfer transaction, improved underlying operating results, and A.M. Best's recent affirmation of Hallmark's Financial Strength Rating of A-. The Hallmark Board will continue to evaluate all actions that may enhance shareholder returns. The results of future analysis could differ materially from the present indications for a variety of reasons including potential fluctuations in operating results, management of growth and surplus, market conditions, competition, new business opportunities and the timing of related investments.

10:47 EST Forward Pharma trading resumes

10:42 EST Forward Pharma trading halted, volatility trading pause

10:12 EST Sera Prognostics Inc (Class A Stock) trading halted, volatility trading pause

10:00 EST United States Natural Gas Fund falls -5.7% - United States Natural Gas Fund is down -5.7%, or -73c to $11.99.

10:00 EST Zhangmen Education falls -10.4% - Zhangmen Education is down -10.4%, or -88c to $7.60.

10:00 EST Lightning eMotors rises 10.5% - Lightning eMotors is up 10.5%, or 61c to $6.44.

09:52 EST Society Pass Inc trading resumes

09:47 EST Society Pass Inc trading halted, volatility trading pause

09:47 EST Urstadt Biddle Properties Inc. falls -5.1% - Urstadt Biddle Properties Inc. is down -5.1%, or -97c to $18.25.

09:47 EST Innovid rises 8.1% - Innovid is up 8.1%, or 57c to $7.57.

09:47 EST Turkcell rises 10.0% - Turkcell is up 10.0%, or 37c to $4.07.

09:33 EST Inpixon's CXApp platform selected by Association of Briefing Program Managers - Inpixon nnounced its CXApp event platform has been selected by the Association of Briefing Program Managers as the exclusive event management solution for the group's three conferences as well as their virtual workshops and member meetings in 2022. ABPM is a global professional community that advances briefing programs as a vital tool for the success of its member companies.

09:29 EST FDA grants Merck Emergency Use Authorization for molnupiravir for COVID-19 - The FDA stated in a letter posted to its website that it is authorizing the emergency use of molnupiravir for the treatment of mild-to-moderate COVID-19 in adults who are at high-risk for progression to severe COVID-19, including hospitalization or death. The FDA said in its letter that "it is reasonable to believe that molnupiravir may be effective for the treatment of mild-to-moderate COVID-19 in adults who are at high-risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate." Reference Link

09:27 EST TCI comments on CEO search process at Canadian National, urges board changes - Long-term shareholders CIFF Capital UK LP and The Children's Investment Master Fund, acting by their investment manager TCI Fund Management Limited, commented on the CEO search process at Canadian National Railway and reiterated the urgent need for change on the CN Board of Directors. The full statement from TCI follows: "Given the CN Board's history of failed CEO appointments, it is not a surprise to us that the Board has failed once again to attract the best candidate for the role. The Board is conflicted, which makes the current selection process flawed and unreliable. A CEO needs to be certain that he or she will have the unwavering support of the Board, and currently that cannot be guaranteed. If CN shareholders elect the four independent candidates nominated by TCI at the Special Meeting they can be confident the Board will conduct a fair CEO selection process and be able to offer the new CEO stable and durable support. The need for change on the CN Board has never been more apparent and TCI remains fully committed to bringing much-needed railroad experience to the Board for the benefit of all CN shareholders. Gil Lamphere, Rob Knight, Allison Landry and Paul Miller also remain committed to standing for election at the Special Meeting and working with the rest of the Board to appoint the best CEO for CN. The appointment of the new CEO should therefore be delayed until after the Special Meeting so shareholders can vote on who should conduct the vitally important search for a CEO who can initiate an operational transformation which will pave the way for future growth. The four independent and highly-skilled nominees have vast railroad experience and knowledge, and they share a common and very achievable goal: to create a much-needed culture of operational excellence at CN, which is essential if the company is to reach its full potential. A new, high-quality board with extensive railroad experience and expertise will help ensure CN is put on the right track to the benefit of the Canadian and US economies, shippers, employees and shareholders."

09:22 EST Container Store announces changes to board of directors - The Container Store announced the election of Lisa Klinger as a Class III Director, effective March 29, 2022. She will also serve on the Audit Committee. Klinger will replace Timothy Flynn, who has resigned from the Board of Directors effective on March 29, 2022.

09:21 EST Medigus says Polyrizon to test product candidate for omicron variant - Medigus announced that Polyrizon Ltd., a privately held company which Medigus owns 35.86% of its share capital, will evaluate the viral infection prophylaxis effect of its product candidate against the Omicron variant of the coronavirus in-vitro. This study follows recent pre-clinical studies showed strong potential against human coronavirus 229E and influenza virus infection. The Omicron variant is rapidly spreading a variant of SARS-CoV-2, demonstrating an unusually high number of novel mutations, affecting the spike protein targeted by most COVID-19 vaccines and classified as a Variant of Concern by the center for disease control and prevention. Polyrizon is planning to assess the protection effect of its Capture and Contain platform against the recently reported emerged variant. The study is planned to begin in Q1 2022 in collaboration with Prof. Fabio Sonvico from the Department of Food and Drug Science of Parma University, Italy. The frequently emerging new highly contagious COVID-19 variants highlights the need for prevention solutions to reduce the infection and transmission of these viruses. Polyrizon's C&C platform is a prevention-focused approach that when combined with vaccination, social distancing, hygiene practices and mask usage should further decrease the risk of infection.In an ongoing pre-clinical studies Polyrizon product is tested for Protection against the high transmissible corona viruses, the Delta variant lineage B.1.617.2 and the Gamma variant lineage P.1.

09:17 EST Matterport appoints Peter Presunka as CAO - Matterport announced that Peter Presunka has joined the company as Chief Accounting Officer. Presunka will oversee Matterport's financial reporting, technical accounting, tax and corporate internal controls functions. He will also serve as the Principal Accounting Officer under SEC guidelines. Presunka joins Matterport from SOAProjects, Inc., where he was responsible for SEC reporting and technical account projects including revenue recognition, stock-based compensation, and purchase price accounting relating to acquisition transactions

09:10 EST OpenText completes acquisition of Zix, sees accretion - OpenText (OTEX) announced that it has completed the closing of the previously announced acquisition of Zix (ZIXI). OpenText expects no material revenue or operating expenses from Zix over the holiday season between December 23rd and 31st, within the current quarter. The deal is seen as accretive and expected to be on the OpenText operating model within 12-18 months.

09:08 EST NorthView Acquisition announces closing of $189.75M initial public offering - NorthView Acquisition announced the closing of its initial public offering of 18,975,000 units, which included the full exercise of the underwriters' over-allotment option, at a price to the public of $10.00 per unit. The units began trading on the Nasdaq Global Market under the symbol "NVACU" on December 20, 2021. Each unit consists of one share of common stock, one right, and one-half of one redeemable warrant. Each right entitles the holder to receive one-tenth of one share of common stock upon the consummation of an initial business combination. Each whole warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the common stock, rights and warrants are expected to be traded on the Nasdaq Global Market under the symbols "NVAC," "NVACR" and "NVACW," respectively. I-Bankers Securities, Inc. acted as the sole book-running manager of the offering and Dawson James Securities, Inc. acted as co-manager of the offering.

09:06 EST FDA authorizes marketing of 22nd Century's 'VLN King' and 'VLN Menthol King' - The U.S. Food and Drug Administration announced it has authorized the marketing of 22nd Century Group's "VLN King" and "VLN Menthol King" combusted, filtered cigarettes as modified risk tobacco products, or MRTPs, which help reduce exposure to, and consumption of, nicotine for smokers who use them. "These are the first combusted cigarettes to be authorized as MRTPs and the second tobacco products overall to receive 'exposure modification' orders, which allows them to be marketed as having a reduced level of, or presenting a reduced exposure to, a substance," the FDA said. "Our mission is to find ways to stop tobacco-related disease and death. We know that three out of four adult smokers want to quit and the data on these products show they can help addicted adult smokers transition away from highly addictive combusted cigarettes. Having options like these products authorized today, which contain less nicotine and are reasonably likely to reduce nicotine dependence, may help adult smokers. If adult smokers were less addicted to combusted cigarettes, they would likely smoke less and may be exposed to fewer harmful chemicals that cause tobacco-related disease and death," said Mitch Zeller, J.D., director of the FDA's Center for Tobacco Products.

09:03 EST Bolt Metals announces conditional sales of Cyclops project - Bolt Metals announced it has entered into a conditional share sale and purchase agreement, pursuant to which Nickel Mines has agreed to acquire 100% of the Company's interest in the Cyclops nickel-cobalt project. Pursuant to the Agreement and subject to approval of the Transaction by the shareholders of Bolt, Bolt and its subsidiaries will receive cash payments in the aggregate amount of $6,020,000 in exchange for the Company's 65% interest in the Cyclops project, a 5,000 hectare nickel-cobalt project located in Papua province, Indonesia. If the shareholders of the Company do not approve the Transaction, Nickel Mines will have the right to acquire a 45% interest in the Cyclops Project for total consideration to the Company and its subsidiaries of $750,000 and additional consideration to underlying Cyclops Project owners of $980,000. Completion of the Transaction is subject to customary due diligence, regulatory and shareholder approval and the successful extension of the Production Operation IUP mining permit for the Cyclops Project. A finder's fee is payable in connection with the Transaction. Pursuant to the Agreement and subject to Bolt shareholder approval of the Transaction, Nickel Mines will acquire a 100% interest in the Cyclops Project in consideration for the payment of an aggregate of $8,500,000 in cash, payable as follows: $500,000 payable to Bolt within seven business days of entering into the Agreement and $6,020,000 payable on closing of the Transaction to Cobalt Power, an indirect wholly-owned subsidiary of Bolt, to acquire all the issued and outstanding shares of Minerals Harvest. $980,000 payable to PT Best Resources to acquire the remaining 35% interest in the Cyclops Project. $1,500,000 payable to an existing royalty-holder to buy out a 2% NSR royalty granted by CPA on the Cyclops Project. In the event Bolt does not obtain shareholder approval for the Transaction, Nickel Mines has the right to acquire a 45% interest in the Cyclops Project by paying $250,000 to Bolt for a 10% interest in MHL, paying $250,000 to CPA in exchange for CPA cancelling its option to acquire an additional 35% interest in the Cyclops Project and paying $980,000 to PT Best to acquire their 35% interest in the Cyclops Project, following which Nickel Mines and Bolt will proceed as partners in developing the Cyclops Project with Nickel Mines holding a 45% interest and Bolt holding the remaining 55% interest in the project. Nickel Mines may also elect to terminate the Agreement and receive a cash payment of $250,000 if Bolt does not obtain shareholder approval for the Transaction.

09:03 EST Arthur J. Gallagher acquires Five Points Benefits Solutions, terms undisclosed - Arthur J. Gallagher & Co. announced the acquisition of Franklin, Tennessee-based Five Points Benefits Solutions. Terms of the transaction were not disclosed. Founded in 2011, Five Points is an employee benefits consultant and premier regional provider of ancillary benefits, such as life, disability, dental and vision coverages, to public-sector clients throughout Tennessee, as well as in Georgia and Kentucky.

08:40 EST Phunware partners with PrimusTech for integration of mobile Smart Solutions - Phunware announced that it has partnered with PrimusTech to integrate and offer its Smart Solutions on mobile. Based in Singapore, PrimusTech is a Master System Integrator that offers a comprehensive range of services and solutions to support digital transformation that include Integrated Building Management Systems, Smart Facility Management Systems, Internet of Things/Data Analytics, Extra-Low Voltage Systems, Network Infrastructure and Infocomm Technology solutions.

08:36 EST Global Technologies to spin-off subsidiary Markets on Main to shareholders - Global Technologies announced that the Company will spin-off its wholly owned subsidiary, Markets on Main, LLC to shareholders. On December 17, 2021, the Company's Board of Directors approved a corporate action to file a Notice of Conversion with the State of Florida for its wholly-owned subsidiary, Markets on Main, LLC, which will convert the Subsidiary from a limited liability company to a for profit corporation. The Subsidiary's name will change to Markets on Main. In the newly filed Articles of Incorporation for the Subsidiary, it will authorize 500 million shares of common stock and 10 million shares for preferred stock. Shareholders of Global Technologies, will receive a pro rata number of shares of the Subsidiary based on the number of shares of GTLL held as of the Record Date. The spin-off is one of the transactions to be completed in the Tersus Power merger. The Company will release information by mid-January 2022 with the definitive Record Date and ratio. After the spin-off, the Company will retain a 19.99% interest in MOM, with 80.01% of the common shares of MOM distributed to the GTLL common shareholders. The Company anticipates filing the corporate action with the Financial Industry Regulatory Authority shortly after the closing of the Tersus Power merger transaction. The Company will file a Registration Statement with the Securities and Exchange Commission for the shares of MOM issued to the GTLL shareholders. The shares will initially be issued in book entry format and then electronically transferred. The Company will create a Stock Dividend page on its website so that shareholders may follow the progression of the stock dividend.

08:35 EST ISS, Glass Lewis recommend Calibre shareholders vote for Fiore Gold transaction - Calibre Mining (CXBMF) announced that independent proxy advisory firms, Institutional Shareholder Services and Glass Lewis & Co. have each recommended Calibre shareholders vote "FOR" the resolution approving the issuance of common shares of Calibre pursuant to the plan of arrangement whereby Calibre will acquire all of the issued and outstanding common shares of Fiore Gold (FIOGF). The board of directors of Calibre unanimously determined that the Arrangement is in the best interests of Calibre and unanimously recommends that Calibre Shareholders vote FOR the Share Issuance Resolution at the special meeting of the Calibre Shareholders to be held on January 5, 2022 at 10:00 a.m. to consider, among other things, the Share Issuance Resolution.

08:32 EST ToughBuilt launches ToughBuilt Workbench line - ToughBuilt Industries announced that it has launched a new product line, the ToughBuilt Workbench, which is now available for purchase across its strategic global partners and buying groups servicing over 14,400 stores globally.

08:28 EST Bridgeline Digital enters deal with promotional product seller - Bridgeline Digital announced that an online marketing promotional product company has chosen their site search product to power their on-site search experience.

08:16 EST Virgin Orbit announces it completed final launch rehearsal - Yesterday, Virgin Orbit (VORB), which has announced a planned business combination with NextGen Acquisition (NGCA), completed a full wet dress rehearsal of its air-launched LauncherOne satellite delivery service. With this critical test successfully completed and the bonus of adding an additional satellite to the payload stack earlier this month, Virgin Orbit is tracking towards a launch in January 2022. The launch window is set to open January 12th, 2022, and the launch itself will be livestreamed to the public.

08:15 EST Vallon Pharmaceuticals achieves last patient visit in SEAL study of ADAIR - Vallon Pharmaceuticals announced that the last patient has completed their final visit in the pivotal SEAL intranasal abuse study evaluating ADAIR, a proprietary abuse-deterrent formulation of immediate-release dextroamphetamine for the treatment of attention deficit hyperactivity disorder and narcolepsy. The SEAL study, is the Company's pivotal intranasal human abuse liability study assessing the pharmacodynamics, pharmacokinetics, safety and tolerability of snorting professional laboratory-manipulated ADAIR 30 mg when compared to crushed d-amphetamine sulfate and placebo in recreational drug users. Safety will be assessed via adverse events, vital signs, ECGs, clinical laboratory tests and other standard measures. The SEAL study enrolled 55 subjects who successfully passed the qualification phase with a total of 53 completing the study. The primary endpoint of the study is Emax Drug Liking, a standard abuse liability parameter typically used in human abuse liability studies. The study was designed with 90% powering to show a statistically significant difference between snorted ADAIR after professional manipulation compared to snorted crushed dextroamphetamine. In the previously reported VAL-103, proof of concept human abuse liability study with 16 subjects, snorted manipulated ADAIR showed a statistically significant difference compared to crushed and snorted dextroamphetamine on the same endpoint. ADAIR is being developed leveraging the de-risked 505(b)(2) regulatory pathway. If approved, ADAIR has the potential to address the growing Adderall segment of the ~$9B US ADHD market.

08:13 EST Codex DNA releases full-lenfth synthetic genome for SARS-CoV-2 omicron variant - Codex DNA announced the release of a new full-length synthetic genome of the SARS-CoV-2 virus for the highly mutated and contagious Omicron variant. Omicron has been identified as a Variant of Concern by WHO and is spreading more rapidly than any other previous variant of SARS-CoV-2. The genome was built with the company's BioXp 3250 system, a fully automated synthetic biology benchtop workstation for rapid, accurate, and reproducible writing of DNA and mRNA. With the Omicron variant, Codex DNA offers a full catalogue of 14 SARS-CoV-2 synthetic genomes as well as custom-made SARS-CoV-2 genomes that are used to support researchers in their search for solutions to fight specific variants. In addition, Codex DNA offers custom DNA synthesis services to address the global pandemic. For customers interested in alternative variants to SARS-CoV-2, Codex DNA provides a wide range of synthetic controls that enable scientists to confidently verify and validate assays without the need for clinical virus samples.

08:11 EST Bowman Consulting announced acquisition of 1519 Surveying - Bowman Consulting (BWMN) announced the acquisition of 1519 Surveying. 1519 delivers a variety of engineering and survey solutions to a diverse base of private and public clients. Services include land surveying, aerial imaging, GIS mapping, 3-D laser scanning and civil engineering. "With 1519, Bowman adds tremendous depth in the Texas surveying, engineering and geomatics markets," said Gary Bowman, CEO of Bowman. "The 1519 team is an impressive group with a solid command of their markets and an appetite for growth that aligns well with Bowman's strategy. 1519 is a recognized leader in serving the energy transition market with broad experience in large scale wind farms and utility scale photovoltaic facilities. The firm's experience with the Texas DOT fits well with our commitment to growing our transportation and infrastructure business. When it comes to oil and gas clients, the professionals at 1519 are highly experienced in providing services to the upstream and midstream petrochemical industry. We're excited to begin working together and integrating the 1519 team into Bowman's national network."

08:09 EST Virgin Orbit licenses QuantumCloud from Arqit - Virgin Orbit (VORB), the responsive launch and space solutions company that has announced a planned business combination with NextGen Acquisition (NGCA), has signed a new launch contract covering two dedicated launches for Arqit Quantum (ARQQ). The two Arqit satellites delivered to Earth orbit by Virgin Orbit's LauncherOne air-launched system will be the core component of Arqit's Platform-as-a-Service, delivering the root source of randomness to all Arqit data centres using Arqit's ground-breaking Quantum protocol ARQ19. Arqit and Virgin Orbit are collaborating on responsive space initiatives serving the nations of the Five Eyes international intelligence alliance, comprising of Australia, Canada, New Zealand, the United Kingdom, and the United States. Arqit has committed to launch such additional customer funded systems exclusively with Virgin Orbit, and that contract allows for up to five launches that will be realized as anticipated government contracts move forward to utilize Arqit's services. The parties also announce that the QuantumCloud Software License signed between the companies in parallel to the launch services agreement will also enable Virgin Orbit to use Arqit's world-leading platform to provide market-leading encryption to secure Virgin Orbit's global infrastructure. Thus, Virgin Orbit becomes the world's first quantum safe launch services provider.

08:08 EST Cerence signs $149M contract with large European automaker - Cerence announced it has signed the largest contract in the company's history. Cerence has signed a contract with a valuation of $149M with a large European automaker for its connected, conversational AI automotive assistant products. This contract is significant for the company both in its size and as a validation of continued OEM partnership and commitment to deeply integrated, custom-branded in-car assistant experiences.

08:07 EST Quidel falls 12% to $146 after announcing $6B deal to acquire Ortho Clinical

08:05 EST The Tile Shop appoints Karla Lunan as CFO - Tile Shop Holdings (TTSH) announced that Karla Lunan will be joining the Tile Shop as its new CFO on January 3, 2022. To help ensure a smooth transition, Lunan will work closely with the Company's current CFO Nancy DiMattia, who will remain with the company in an advisory capacity through March 31, 2022. Prior to joining the Tile Shop, Lunan worked at MasTec (MTZ) for 6 years, most recently serving as a CFO within the Clean Energy and Infrastructure Group.

08:04 EST Ayr Wellness opens 43rd Florida location in Eustis - Ayr Wellness announced the opening of its newest dispensary in Eustis, Florida. The dispensary will occupy over 3,000 square feet of retail space in the lakeside city of Eustis, just south of The Villages, a 55+ community. The store is the first Florida dispensary to have been fully designed and built by the Ayr team and incorporates design elements inspired by the company's upcoming Boston-area flagship dispensaries in Back Bay and Watertown.

08:03 EST Thor Industries announces MoU with ZF Friedrichshafen for eTrailer System - Thor Industries announced the execution of a binding Memorandum of Understanding with ZF Friedrichshafen AG which outlines the parties' joint development of a proprietary high voltage electric drive system for towable recreational vehicles. The development driven by Thor and ZF is designed to maintain, and possibly extend, the nominal range of an electric vehicle when towing a trailer.

08:02 EST Opko Health announces results from Phase 2 trial of RAYALDEE - OPKO Health announces preliminary topline results from its Phase 2 trial with RAYALDEE to treat mild-to-moderate COVID-19. This study builds on increasing medical evidence that vitamin D repletion therapy can mitigate the severity of upper respiratory tract infections and accelerate recovery from COVID-19. RAYALDEE, after oral administration, gradually releases calcifediol, the natural storage form of vitamin D3, to safely and reliably raise a patient's serum total 25-hydroxyvitamin D well above current targets of 20 or 30 ng/mL. RAYALDEE is approved in the U.S. and many European countries for treating secondary hyperparathyroidism in non-dialysis chronic kidney disease patients by raising 25D to levels as high as 100 ng/mL. In the Phase 2 trial, titled "A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of RAYALDEE Extended-release Capsules to Treat Symptomatic Patients Infected with SARS-CoV-2," 171 symptomatic COVID-19 outpatients were enrolled from multiple U.S. sites and randomized in a 1:1 ratio for 4 weeks of treatment with RAYALDEE or placebo and a 2-week follow-up. Dosing with RAYALDEE was designed to progressively raise serum 25D to 50 to 100 ng/mL by Day 7, beginning with 300 mcg on Days 1, 2 and 3 followed by 60 mcg per day on Days 4 through 27. COVID-19 symptoms were self-reported daily during the 42-day study using the FLU-PRO Plus questionnaire, an outcome tool validated for upper respiratory tract infections. Blood samples and safety assessments were obtained at 7-day intervals. One primary efficacy endpoint was reaching the targeted serum 25D level. By Day 7, mean serum 25D levels increased with RAYALDEE treatment to 82 ng/mL and remained elevated for the duration of the trial, with 88% of subjects attaining the targeted level. In contrast, mean 25D declined slightly with placebo treatment. A second primary efficacy endpoint was the benefit of raising serum 25D on the time to resolution of five COVID-19 symptoms: trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering. The three symptoms related to respiratory function, evaluated together, resolved more quickly when serum 25D was elevated at Days 7 and 14, with resolution of chest congestion occurring 3.4 days sooner. In subjects achieving increases in serum 25D of at least 25 ng/mL, chest congestion resolution occurred 4 days earlier. The mean time to resolution for all five symptoms considered in aggregate was not significantly different between the treatment groups since symptoms unrelated to respiratory function were unresponsive to treatment. The average age of enrolled subjects was 43; 57% were female, 93% White, 6% African-American,1% Other. Nearly 40% were obese and 79% overweight, based on body mass index greater than 30 or 25, respectively. Approximately 30% had comorbidities, most commonly hypertension. Safety endpoints included vital signs, physical examinations, adverse events, electrocardiograms and biochemical assessments, all of which showed no meaningful changes with treatment.

08:01 EST Canadian Pacific, Canpotex enter new long-term agreement - Canadian Pacific announced the execution of a new long-term agreement with Canpotex Limited further cementing the long-standing relationship between the two companies and supporting Canpotex's future growth. CP is the primary rail transportation provider supporting delivery of Canadian potash to Canpotex's overseas export markets. The new seven-year contract, which runs through 2028, is a successor to the current, 10-year agreement between CP and Canpotex, which expires in 2022.

07:36 EST US Energy Initiatives Corp deposits digital assets for sale - US Energy Initiatives announces that the Company has transferred $10M of its digital assets to BMCS SUMCOIN INDEX FUND dba Bio Tech Medics to be sold at "market value' to generate capital to execute its 2022 Business Plan that includes "green energy mining" and the entrance into the Metaverse sector. According to Anthony Miller, CEO, "Today we announce that the Company has done what it reported in its December 14, 2021 press release, transferring $10 million dollars of its digital asset into position to be sold. Management hopes that the currency should be sold in the first few months of 2022. The BMCS business plan is designed to provide worldwide holders with an exit strategy for their Sumcoin that will turn their digital currency into US dollars, and receive the fair market value for their assets. When the capital is available, Management will initiate a significant mining operation that encompasses green energy as the source of power. Management has done significant research on this operation and believes that the revenue projections will be outstanding. Additionally, Management has been investigating opportunities for the Company in the Metaverse. What is the Metaverse? It's a combination of multiple elements of technology, including virtual reality, augmented reality and video where users 'live' within a digital universe; it also may contain elements or be integrated along with the blockchain technology. Supporters of the Metaverse envision its users working, playing and staying connected with friends through everything from concerts and conferences to virtual trips around to the world. Three years ago folks thought we were crazy for getting into crypto currency and look at us now... recently, we have be dabbling in the NFT space which could be tremendously lucrative, so call us crazy or innovative, either one works. Management believes that everything we have researched tells us that the Metaverse is a great direction for USEI. In the coming weeks we will purchase property and move headlong into this space. This is a long play, the industry is years away but the time is right now for us to get in ahead of the gold rush. Microsoft and Facebook are bullish on the Metaverse sector and have invested millions of dollars in the space so we are in good company. It is our goal that USEI has a very lucrative 2022 and we will continue to transfer Sumcoin on consignment, over the year, as the BMCS venture continues to provide us with cash to grow this firm. We are excited about the future beyond 2022... our digital assets are the life blood of this firm."

07:30 EST Ackrell SPAC Partners I Company (Units) trading resumes

07:30 EST InnovAge Holding Corporation trading resumes

07:30 EST Ortho Clinical Diagnostics trading resumes

07:27 EST Ortho Clinical Diagnostics trading halted, news pending

07:27 EST Ackrell SPAC Partners I Company (Units) trading halted, news pending

07:18 EST Microbix expects to generate 'meaningful net earnings growth' across 2022 - The company said, "Microbix will continue to drive sales growth across all of its three revenue-generating business lines, and work to keep improving percentage gross margins and driving bottom-line results. Management currently expects Microbix to generate meaningful net earnings growth across fiscal 2022. Additionally, work continues upon securing a partnership to advance its Kinlytic urokinase project."

07:16 EST LabCorp to acquire Personal Genome Diagnostics for $450M in cash - Labcorp announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics, PGDx. "Labcorp's leadership and scale in diagnostic testing and drug development, coupled with PGDx's innovative technology and suite of capabilities, will accelerate access to personalized treatments for cancer patients globally," said Adam Schechter, chairman and CEO of Labcorp. "PGDx's comprehensive portfolio of next-generation sequencing products will meaningfully add to our breadth of capabilities, in line with our strategic priority to lead in oncology. PGDx's technology is well positioned in an important segment with strong growth prospects. We look forward to welcoming PGDx's talented team and working together to bring world-class diagnostics, technology and treatments within reach for all." Under the terms of the agreement, Labcorp will pay $450M in cash at closing and up to an additional $125M on achieving future performance milestones. The transaction is subject to customary closing conditions and regulatory approvals. The transaction is expected to close in the first half of 2022.

07:13 EST B.O.S. Intelligent Robotics Division receives order from Israeli customer - BOS Better Online Solutions announced that its Intelligent Robotics Division has received an order of $216,000 from an Israeli strategic customer.

07:11 EST InnovAge announces audit sanctions in Colorado - InnovAge Holding announced that the Centers for Medicare and Medicaid Services has sanctioned the Company's Colorado centers based on deficiencies detected in a focused audit. On December 22, 2021 InnovAge was notified that CMS had determined to suspend new enrollments at the Company's Colorado centers based on deficiencies detected in an audit that was conducted earlier this year the final results which have not yet been disclosed to the company. CMS identified the following deficiencies including a failure: To provide all Medicare and Medicaid covered services, as well as other services determined necessary by the interdisciplinary team to improve and maintain the participant's overall health status; To provide care that meets the needs of each participant across all care settings, 24 hours a day, every day of the year; To ensure accessible and adequate services to meet the needs of the Company's participants; Of the IDT to coordinate 24-hour care delivery and to remain alert to pertinent information from other team members, participants, and caregivers; and Of the InnovAge Colorado's primary care providers to manage their participants' medical situations and oversee their participants' use of medical specialists. CMS indicated that the suspension will remain in effect until it determines that the Company has remedied such deficiencies to its satisfaction. The Colorado Department of Health Care Policy and Financing has verbally communicated that they are also issuing sanctions in conjunction with CMS and will provide written communication on December 23rd, 2021, identifying the deficiencies specific to Medicaid. The Company continues to work with CMS and HCPF to respond to the sanctions and is evaluating its options with regard to its rights to appeal the sanctions from both CMS and HCPF. The Company cannot guarantee the outcome of any of these processes.

07:06 EST Quidel sign definitive agreement to acquire Ortho Clinical for $24.68 per share - Quidel (QDEL) and Ortho Clinical Diagnostics (OCDX) announced that they have entered into a definitive agreement in which Quidel will acquire Ortho for $24.68 per share of common stock using a combination of cash and newly issued shares in the combined company, representing a 25% premium over Ortho's closing price on December 22, 2021 and an equity value of approximately $6B. The transaction is expected to close during the first half of fiscal year 2022, subject to customary closing conditions. "The combination with Ortho will help solidify Quidel as a leader in the diagnostics industry, bringing together innovative, complementary products, solutions, and services that enhance the health and well-being of patients across the globe," said Douglas Bryant, President and Chief Executive Officer of Quidel, who will serve as Chairman and Chief Executive Officer of the combined company. Transaction Details: Under the terms of the agreement, which was unanimously approved by the Board of Directors of each company, Quidel will acquire Ortho for $24.68 per share of common stock, for a total consideration of approximately $6B, including $1.75B of cash, funded through cash on the balance sheet and incremental borrowings. The combined company will also acquire Ortho's existing net debt of $2B. Ortho shareholders will receive $7.14 in cash per common share and 0.1055 shares of common stock in the combined company for each Ortho common share, with Ortho shareholders expected to own approximately 38% of the combined company. This represents an implied premium of 25% when compared to Ortho's unaffected closing stock price on December 22, 2021. Following the close of the transaction, the combined company's Board of Directors will consist of 12 members, eight designated by Quidel and four designated by Ortho. Quidel's current President and Chief Executive Officer, Douglas Bryant, will serve as Chairman and Chief Executive Officer of the combined company. Joseph Busky will be the Chief Financial Officer, Robert Bujarski will be President and Chief Operating Officer, and Michael Iskra will be Chief Commercial Officer. The transaction, which is subject to approval by both companies' shareholders as well as customary closing conditions and regulatory approvals, is expected to close in the first half of 2022.

07:04 EST Taysha Gene Therapies added to ICE Biotechnology Index - Taysha Gene Therapies announced that it has been added to the ICE Biotechnology Index in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Monday, December 20, 2021. "Taysha's inclusion in this key biotechnology index provides important validation of our platform and value proposition as a company," said RA Session II, President, Founder and CEO of Taysha. "We remain focused on executing our near-term clinical and regulatory milestones, which we believe will continue to increase our visibility within the investment community."

07:02 EST P10 announces $250M debt refinancing - P10 has entered into a $250M credit facility with a syndicate of banks led by JPMorgan Chase Bank, N.A. and Texas Capital Bank. The new credit facility provides for a term loan in the amount of $125M and a revolving commitment in the amount of $125 million. The company will use the loan proceeds to pay off the outstanding borrowings under its existing credit facility, pay off seller's notes related to the RCP acquisition, and pay transaction-related expenses, as well as for working capital and other general corporate purposes. Terms of the new credit facility call for a variable interest rate of approximately two and a quarter percent which offers significant savings over the seven percent interest rate with the previous credit agreement. The credit agreement contains customary financial covenants as well as affirmative and negative covenants customary for transactions of this type.

07:00 EST Crocs to acquire HEYDUDE for $2.5B

06:33 EST EU commercial vehicle registrations down 14.7% in November - In November, new commercial vehicle registrations across the EU retreated 14.7%, falling for the fifth consecutive month, reported the European Automobile Manufacturers Association. "The van segment's double-digit drop weighed heavily on the overall result, as vans accounted for over 80% of total commercial vehicle sales in the European Union. The region's four major markets posted strong declines last month, with the sharpest drop seen in Spain of 30.4%," the group said. Publicly traded truck makers and suppliers include Daimler AG (DDAIF), Paccar (PCAR), CNH Industrial (CNHI), Navistar (NAV), Cummins (CMI) and Allison Transmission (ALSN).

06:30 EST Novartis reports Cosentyx receives FDA approval in new indication for children - Novartis announced the U.S. Food and Drug Administration has approved Cosentyx for the treatment of active enthesitis-related arthritis in four years and older, and active juvenile psoriatic arthritis in patients two years and older. "Cosentyx is now the first biologic indicated for ERA, and the only biologic treatment approved for both ERA and PsA in pediatric patients in the US. These are the second and third approvals for Cosentyx in a pediatric population in the US, and Cosentyx now has a total of five indications across rheumatology and dermatology," the company stated.

06:23 EST AstraZeneca's Evusheld retains neutralisation activity against omicron - The company states that its "Evusheld, tixagevimab co-packaged with cilgavimab, a long-acting antibody combination for the prevention of COVID-19, retains neutralisation activity against the Omicron SARS-CoV-2 variant, according to new authentic 'live' virus neutralisation data from both University College Oxford, UK and Washington University School of Medicine, St. Louis, US. Evusheld's Inhibitory Concentration 50, a measure of neutralising potency of an antibody, was 273 ng/ml and 147 ng/ml in the Oxford and Washington University studies, respectively. The levels are within the range of neutralising antibody titres found in individuals who have been previously infected with and recovered naturally from COVID-19. The data were generated from laboratory testing using actual live virus isolated from individuals who contracted the Omicron variant of COVID-19, considered a 'gold standard' for antibody neutralisation studies.4 Evusheld is one of only two antibody therapies authorised for use that showed neutralising activity against Omicron and against all other variants of concern in these two studies."Reference Link

06:06 EST LumiraDx receives CE Mark for SARS-CoV-2 & Flu A/B Antigen Test - LumiraDx announced its SARS-CoV-2 & Flu A/B Antigen Test has achieved CE Marking. The microfluidic immunofluorescence assay can quickly verify potential infection for patients suspected of influenza and/or COVID-19, helping to identify and differentiate the underlying cause of respiratory illness and to inform treatment decisions at the point of care. Existing respiratory tests on the LumiraDx Platform include the company's SARS-CoV-2 Antigen, SARS-CoV-2 Antibody and SARS-CoV-2 Antigen Pool tests which achieved CE Marking in August 2020, September 2020 and March 2021, respectively.

06:02 EST AdTheorent to begin trading on Nasdaq - AdTheorent (ADTH) announced that it has completed its business combination with MCAP Acquisition Corporation (MACQ). The Business Combination was approved by MCAP stockholders in a special meeting on December 21, and formally closed on December 22. AdTheorent shares will begin trading December 23 on Nasdaq under the ticker symbol "ADTH" and its warrants will trade under the ticker symbol "ADTHW".

05:54 EST Philips, IJsselland Hospital sign long-term technology partnership - Royal Philips announced it has signed a 12-year strategic partnership with IJsselland Hospital. As the hospital's strategic technology partner, Philips will target improved care for patients and care providers at IJsselland Hospital and in the surrounding region. The collaboration will focus on innovation, digitalization and optimization, and includes the purchase of patient monitoring and radiology solutions including CT and MRI systems. In addition to the new strategic partnership, Philips and IJsselland Hospital plan to expand their existing home monitoring partnership for patients with heart failure and COPD. Philips will provide clinical and patient decision support software which enables implementation of remote health and care programs and facilitates collaboration between different healthcare providers.

05:51 EST Applied Materials, Institute of Microelectronics expand research pact - Applied Materials and the Institute of Microelectronics, a research institute of Singapore's Agency for Science, Technology and Research, announced a new phase of their research collaboration at the Center of Excellence in Advanced Packaging in Singapore. Under the new phase of their R&D engagement, Applied Materials and A STAR's IME aim to accelerate the AI era of computing by driving breakthroughs in heterogeneous integration and advanced packaging for semiconductor innovation. The parties have signed a five-year extension to their existing research collaboration and will make a new, combined investment of approximately $210M to upgrade and expand the Center of Excellence in Advanced Packaging in Singapore to accelerate materials, equipment and process technology solutions for hybrid bonding and other emerging, 3D chip integration technologies.

05:47 EST Yellowstone Acquisition announces additional $45M PIPE financing - Yellowstone Acquisition announced that Boston Omaha Corporation, through its subsidiary BOC YAC, LLC, has agreed to provide $45M of PIPE financing in connection with the closing of the potential business combination with Sky Harbour, in addition to the $55M Series B investment that will convert to Class A common stock upon completion of the business combination. Boston Omaha is committing $100M in total to Sky for the acceleration of Sky's business plan. The PIPE Financing will be provided through the purchase of Yellowstone Class A common stock at a price of $10.00 per share immediately prior to the closing of the business combination. BOC YAC, LLC has executed a PIPE Subscription Agreement to provide the additional $45M in equity financing. In consideration of the investment, Sky has agreed to waive the $150M minimum financing condition which required that the company deliver cash proceeds of at least $150M to Sky as a condition precedent to consummating the business combination.

04:53 EST Flutter Entertainment acquires Italy's Sisal for EUR 1.91B - Flutter Entertainment announced the acquisition of Sisal, an Italian online gaming operator, from CVC Capital Partners Fund VI for a consideration of EUR 1.913B. The transaction is likely to complete during Q2 of 2022 and is expected to be accretive to adjusted earnings in the first 12 months post-completion. Reference Link